US Ambassador Sergio Gor has underscored the pivotal role of India in the global pharmaceutical landscape and technology partnerships, particularly through the Pax Silica initiative. This highlights a growing trust between the nations as they collaborate on critical supply chains and future technologies.
During the US-India TRUST Initiative event at IIT Delhi, Gor emphasized India's significant contribution to the pharmaceutical sector, noting that around 40% of generic medicines in the U.S. are sourced from India. This reliance illustrates the trust the U.S. places in India, particularly for life-saving pharmaceutical ingredients. The partnership aims to fortify resilient supply chains for active pharmaceutical ingredients and critical medicines.
Gor also highlighted India's impressive investment trajectory, with Indian firms announcing over $20 billion in new investments directed to the U.S., predominantly in pharmaceuticals. This investment is not merely economic; it also aims to mitigate global supply chain risks that could lead to medicine shortages.
Furthermore, India's inclusion in the Pax Silica initiative, which focuses on trusted technology supply chains in areas like AI and semiconductors, marks a significant step in deepening technological cooperation. Gor's remarks reflect a broader commitment to fostering innovation and strategic partnerships, positioning India as a key player in the evolving landscape of global technology and supply chains.